Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

RepliCel Life Sciences Inc (RP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.1250 +0.0000    +0.00%
23/06 - Closed. Currency in CAD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.1150 / 0.1500
  • Day's Range: 0.1150 - 0.1300
Type:  Equity
Market:  Canada
ISIN:  CA76027P4006 
S/N:  76027P400
RepliCel Life Sciences 0.1250 +0.0000 +0.00%
  • General    
  • Chart    
  • News & Analysis    
  • Financials    
  • Technical    
  • Forum    
  • InvestingPro
IndustryLife Sciences Tools & Services
SectorHealthcare
Employees

1

Equity Type

ORD

RepliCel Life Sciences Inc. is a regenerative medicine company. It is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.

Contact Information

Phone 604 248 8730
Fax 604 248 8690

Top Executives

Name Age Since Title
David M. Hall 68 2010 Independent Chairman of the Board
Akimichi Morita - 2021 Member of Clinical Advisor Board
Peter Winston Lewis 65 2011 Independent Director
R. Lee Buckler 55 2014 President, CEO, Corporate Secretary & Director
Ross G. Davidson - 2013 Chairman of Clinical Advisory Board
Tsukasa Kumai - - Member of Clinical Advisory Board
Peter Lowry 57 2018 Independent Director
Jack E. Taunton - 2013 Member of Clinical Advisory Board
Rolf Hoffmann 59 2010 Member of Clinical Advisory Board
David A. Connell - 2013 Member of Clinical Advisory Board
Jean Krutmann - - Member of Clinical Advisory Board
Andrew Schutte 31 2018 Independent Director
Kunihiko Suzuki 62 2021 Senior Strategic Advisor to Directors
Gary Boddington - 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RP Comments

Write your thoughts about RepliCel Life Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nicole Thibs
Nicole Thibs Feb 03, 2021 22:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bonne augmentation
Pascal Duc
Pascal Duc Aug 26, 2019 16:44
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is this ever going to be profitable?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email